By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Eisai R&D
Management Co., Ltd. v. Rea
1:13-cv-00548;
filed May 2, 2013 in the Eastern District of Virginia

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent No. 8,304,548 ("Method for Producing
1, 2-dihydropyridine-2-one Compound," issued November 6, 2012).  View the complaint here.

The Medicines
Company v. Apotex Inc. et al.
3:13-cv-02801;
filed May 1, 2013 in the District of Court of New Jersey

• Plaintiff:  The
Medicines Company
• Defendants: 
Apotex Inc.; Apotex Corp.

Infringement
of U.S. Patent Nos. 7,582,727 ("Pharmaceutical Formulations of Bivalirudin
and Process of Making the Same," issued September 1, 2009) and 7,598,343
(same title, issued October 6, 2009) following a Paragraph IV certification as
part of Apotex's filing of an ANDA to manufacture a generic version of The
Medicines Company's Angiomax® (bivalirudin, used as an anticoagulant in
patients with unstable angina undergoing percutaneous translurninal coronary
angioplasty).  View the complaint here.

Acura
Pharmaceuticals Inc. v. Ranbaxy Inc. et al.
1:13-cv-00750;
filed April 29, 2013 in the District of Court of Delaware

• Plaintiff:  Acura
Pharmaceuticals Inc.
• Defendants: 
Ranbaxy Inc.; Ranbaxy Laboratories Ltd.

Infringement
of U.S. Patent No. 7,510,726 ("Methods and Compositions for Deterring
Abuse of Opioid Containing Dosage Forms," issued March 31, 2009) following
a Paragraph IV certification as part of Ranbaxy's filing of an ANDA to
manufacture a generic version of Oxecta® (oxycodone hydrochloride, used for the
management of acute and chronic moderate to severe pain where the use of an
opioid analgesic is appropriate, marketed by Pfizer).  View the complaint here.

Par
Pharmaceutical, Inc. et al. v. Takeda Pharmaceutical Co., Ltd. et al.
3:13-cv-01927;
filed April 26, 2013 in the Northern District of California

• Plaintiffs: 
Par Pharmaceutical, Inc.; Handa Pharmaceuticals, LLC
• Defendants: 
Takeda Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals North America, Inc.; Takeda
Pharmaceuticals America, Inc; Takeda Pharmaceuticals U.S.A., Inc.

Declaratory
judgment of non-infringement and invalidity of U.S. Patent Nos. 8,105,626 ("Granules
Containing Acid-Unstable Chemicals in Large Amount," issued January 31,
2012) and 8,173,158 ("Methods of Treating Gastrointestinal Disorders
Independent of the Intake of Food," issued May 8, 2012) in conjunction
with Par and Handa's filing of an ANDA to manufacture a generic version of Takeda's
Dexilant® (dexlansoprazole, used for the treatment of all grades of erosive
esophagitis, maintaining healing of esophagitis, and treating heartburn
associated with symptomatic non-erosive gastroesophageal reflux disease).  View the complaint here.